US Expansion Volatility

Grifols’ Phase 3 trials for GAMUNEX‑C and XEMBIFY target U.S. label expansions, potentially broadening future treatment options. The company’s shares trade at €9.85, delivering a 10.36 % return over the past 90 days but falling 12.05 % YTD, creating a contrast between short‑term momentum and longer‑term weakness. Analysts value the stock at €14.40, citing disciplined cost management and deleveraging that have lifted net margins and free‑cash‑flow generation, supporting higher future profit multiples. Nevertheless, high debt and the risk of pricing cuts in key markets remain warning signs.